Polygenic scores for executive functioning as predictors of performance improvements after repeated testing in major psychiatric disorders

Executive Functions (EF) control goal-oriented behaviors and are disrupted in patients with psychiatric disorders (PPD). Repeated EF testing in clinical practice and research aims to evaluate disease progression and treatment efficacy. Performance improvements (or “practice effects”) are expected, while deficiencies had been proposed as markers of conversion to dementia. Given the high conversion risk in PPD, understanding the determinants of practice effects is of high relevance. However, the role of genetic predisposition remains unknown. We aim to test the influence of polygenic scores on practice effects across PPD. Data were drawn from the longitudinal deep-phenotyping PsyCourse Study (N = 1,558). Latent factor analysis revealed a common Executive Function factor (cEF), which explained shared variability of 5 different EF tests. We tested the association of polygenic scores for the cEF (PGS-cEF) – based on the largest GWAS on cEF to date (N = 427,037) - with cEF scores improvements in PsyCourse. The PGS for general psychopathology “p-Factor” (PGS-PF) were used as a psychiatric liability comparison. Volunteer adults (> 18 y.o.), with and without diagnoses within the Affective-Psychotic spectrum were recruited across Germany and Austria, followed-up four times at six months intervals. The mean PGS-cEF was lower in patients with psychotic vs. affective disorders (diff: -0.01, 95% CI -0.02 to -0.002) and controls (diff: -0.02, 95% CI -0.03 - -0.006); while the mean PGS-PF was higher in psychotic vs. affective disorders (diff: 0.02, 95% CI 0.01 to 0.04) and controls (diff: 0.03, 95% CI 0.02–0.05). Overall, the PGS-cEF x Visit interaction was associated with the phenotypic latent cEF scores (eta2 = 0.03; p = 1.32e-15), but not with the scores of individual EF tests. There was no PGS-PF x Visit interaction associated with any cognitive score. To the best of our knowledge, this is the first analysis of genetic factors related to EF improvements in PPD. The PGS-cEF, but not the PGS-PF predicted practice effects in cEF scores over 18 months. This prediction was only observable using the latent‑cEF level, and not with the individual scores. Genetic testing and deep phenotyping might hint further information about EF vulnerability in PPD.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-03-16
DOI
https://doi.org/10.1038/s41598-026-41345-1
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Polygenic scores for executive functioning as predictors of performance improvements after repeated testing in major psychiatric disorders

Kristina Adorjan, Alba Navarro-Flores, Hajar Rafiee, Bernadette Wendel et al.
Scientific Reports
Schizophrenia research and treatment
article

Polygenic scores for executive functioning as predictors of performance improvements after repeated testing in major psychiatric disorders

Kristina Adorjan, Alba Navarro-Flores, Hajar Rafiee, Bernadette Wendel, Carsten Konrad, Jens Reimer, Bernhard T. Baune, Georg Juckel, Andrea Schmitt, Fabian U. Lang, Udo Dannlowski, Andreas J. Fallgatter, Sergi Papiol, Fanny Senner, Thomas G. Schulze, Mojtaba Oraki Kohshour, Max Schmauß, Eva Z. Reininghaus, Daniela Reich-Erkelenz, Monika Budde, Carsten Spitzer, Urs Heilbronner, Peter Falkai, Christian Figge, Maria Heilbronner, Volker Arolt, Ion-George Anghelescu, Jörg Zimmermann, Eva C. Schulte, Detlef E. Dietrich, Jens Wiltfang
article en

Abstract

Executive Functions (EF) control goal-oriented behaviors and are disrupted in patients with psychiatric disorders (PPD). Repeated EF testing in clinical practice and research aims to evaluate disease progression and treatment efficacy. Performance improvements (or “practice effects”) are expected, while deficiencies had been proposed as markers of conversion to dementia. Given the high conversion risk in PPD, understanding the determinants of practice effects is of high relevance. However, the role of genetic predisposition remains unknown. We aim to test the influence of polygenic scores on practice effects across PPD. Data were drawn from the longitudinal deep-phenotyping PsyCourse Study (N = 1,558). Latent factor analysis revealed a common Executive Function factor (cEF), which explained shared variability of 5 different EF tests. We tested the association of polygenic scores for the cEF (PGS-cEF) – based on the largest GWAS on cEF to date (N = 427,037) - with cEF scores improvements in PsyCourse. The PGS for general psychopathology “p-Factor” (PGS-PF) were used as a psychiatric liability comparison. Volunteer adults (> 18 y.o.), with and without diagnoses within the Affective-Psychotic spectrum were recruited across Germany and Austria, followed-up four times at six months intervals. The mean PGS-cEF was lower in patients with psychotic vs. affective disorders (diff: -0.01, 95% CI -0.02 to -0.002) and controls (diff: -0.02, 95% CI -0.03 - -0.006); while the mean PGS-PF was higher in psychotic vs. affective disorders (diff: 0.02, 95% CI 0.01 to 0.04) and controls (diff: 0.03, 95% CI 0.02–0.05). Overall, the PGS-cEF x Visit interaction was associated with the phenotypic latent cEF scores (eta2 = 0.03; p = 1.32e-15), but not with the scores of individual EF tests. There was no PGS-PF x Visit interaction associated with any cognitive score. To the best of our knowledge, this is the first analysis of genetic factors related to EF improvements in PPD. The PGS-cEF, but not the PGS-PF predicted practice effects in cEF scores over 18 months. This prediction was only observable using the latent‑cEF level, and not with the individual scores. Genetic testing and deep phenotyping might hint further information about EF vulnerability in PPD.

Scientific ReportsVol. 16(1)
University of Bern (CH), Ahvaz Jundishapur University of Medical Sciences (IR), University of Padua (IT), Johns Hopkins University (US), University of Hildesheim (DE), Universität Hamburg (DE), The University of Melbourne (AU), Universidade de São Paulo (BR), Medical University of Graz (AT), SUNY Upstate Medical University (US), University of Münster (DE), Florey Institute of Neuroscience and Mental Health (AU), University Hospital Bonn (DE), Johns Hopkins Medicine (US), University Hospital of Bern (CH), German Center for Neurodegenerative Diseases (DE), LMU Klinikum (DE), Medizinische Hochschule Hannover (DE), Klinikum Itzehoe (DE), Klinikum Magdeburg (DE), University Medical Center Hamburg-Eppendorf (DE), Bundeswehrkrankenhaus (DE), Universitätsmedizin Göttingen (DE), University Hospital Magdeburg (DE), Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE), Max Planck Institute of Psychiatry (DE), LWL-Universitätsklinikum Bochum (DE), German Center for Diabetes Research (DE), Agaplesion Diakonieklinikum Rotenburg (DE), Bezirkskrankenhaus Augsburg (DE), University of Rostock (DE), University of Aveiro (PT), FH Münster University of Applied Sciences (DE), University of Göttingen (DE), University of Tübingen (DE), Ludwig-Maximilians-Universität München (DE), Bethel University (US), Ruhr University Bochum (DE)
Openalex Percentile: Top 29%
Schizophrenia research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.